FDA announced a final rule today determining that certain common ingredients, most notably triclosan and triclocarban, in over-the-counter consumer antiseptic washes are not generally recognized as safe and effective (GRAS/GRAE), and thus, can no longer be provisionally marketed under the OTC Drug Review. The final rule affects the status of antibacterial soaps, hand washes, and
More Posts
“Institutional Review Board (IRB) Written Procedures” Draft Guidance and NIH’s “Single IRB Policy” Offer Food for Thought to IRBs Charged with Oversight of Human Subjects Research
FDA Clarifies Expectations for Use of Electronic Health Records in Clinical Investigations
It’s Settled … At Least Somewhat: Settlement of the First Amendment Case Amarin Pharma v. FDA
FDA Settles Pacira’s First Amendment Lawsuit
HHS Proposes Major Changes to Federal Policy for Protection of Human Subjects
Recent First Amendment Rumblings
CEO Media Statements Draw Additional Scrutiny
FDA Withdraws Draft Disease Awareness Guidance
FDA Issues Simpler Draft Form for Individual Patient Expanded Access Applications
Subscribe: Subscribe via RSS
Blogs
Firm/Org